Blood

SCIE

國(guó)際簡(jiǎn)稱：BLOOD 參考譯名：血液

主要研究方向：醫(yī)學(xué)-血液學(xué) 非預(yù)警期刊審稿周期：約1.0個(gè)月

《血液》(Blood)是一本由American Society of Hematology出版的以醫(yī)學(xué)-血液學(xué)為研究特色的國(guó)際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開(kāi)放期刊，近三年沒(méi)有被列入預(yù)警名單。該期刊享有很高的科學(xué)聲譽(yù)，影響因子不斷增加，發(fā)行量也同樣高。

1區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
379 年發(fā)文量
21 IF影響因子
未開(kāi)放 是否OA
426 H-index
1946 創(chuàng)刊年份
Semimonthly 出版周期
English 出版語(yǔ)言

Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.

Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to contact the Editor-in-Chief prior to submission if they are uncertain whether their work falls within the general scope of the journal.

[ 查看全部 ]

投稿咨詢加急咨詢

Blood期刊信息

ISSN：0006-4971
出版語(yǔ)言：English
是否OA：未開(kāi)放
E-ISSN：1528-0020
出版地區(qū)：UNITED STATES
是否預(yù)警：否
出版商：American Society of Hematology
出版周期：Semimonthly
創(chuàng)刊時(shí)間：1946
開(kāi)源占比：0.1201
Gold OA文章占比：26.77%
OA被引用占比：0.0086...
出版國(guó)人文章占比：0.04
出版撤稿占比：0
研究類文章占比：86.54%

Blood CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

23.6

5.272

3.149

學(xué)科類別	分區(qū)	排名	百分位
大類：Biochemistry, Genetics and Molecular Biology 小類：Biochemistry	Q1	11 / 438	97%
大類：Biochemistry, Genetics and Molecular Biology 小類：Hematology	Q1	6 / 137	95%
大類：Biochemistry, Genetics and Molecular Biology 小類：Cell Biology	Q1	18 / 285	93%
大類：Biochemistry, Genetics and Molecular Biology 小類：Immunology	Q1	18 / 236	92%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評(píng)論、會(huì)議論文、書(shū)籍章節(jié)和數(shù)據(jù)論文。

Blood中科院評(píng)價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	HEMATOLOGY 血液學(xué)	1區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	HEMATOLOGY 血液學(xué)	1區(qū)

中科院 2021年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	HEMATOLOGY 血液學(xué)	1區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	HEMATOLOGY 血液學(xué)	1區(qū)

中科院 2021年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	HEMATOLOGY 血液學(xué)	1區(qū)

中科院 2020年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	HEMATOLOGY 血液學(xué)	1區(qū)

Blood JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：HEMATOLOGY	SCIE	Q1	2 / 97	98.5%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：HEMATOLOGY	SCIE	Q1	4 / 97	96.39%

Blood歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Blood中國(guó)學(xué)者發(fā)文選摘

1、PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371
Author: Chen, Hongxia; Bai, Yunpeng; Kobayashi, Michihiro; Xiao, Shiyu; Cai, Wenjie; Barajas, Sergio; Chen, Sisi; Miao, Jinmin; Meke, Frederick Nguele; Vemula, Sasidhar; Ropa, James P.; Croop, James M.; Boswell, H. Scott; Wan, Jun; Jia, Yuzhi; Liu, Huiping; Li, Loretta S.; Altman, Jessica K.; Eklund, Elizabeth A.; Ji, Peng; Tong, Wei; Band, Hamid; Huang, Danny T.; Platanias, Leonidas C.; Zhang, Zhong-Yin; Liu, Yan

Journal: BLOOD. 2023; Vol. 141, Issue 3, pp. 244-259. DOI: 10.1182/blood.2022016580
2、Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes
Author: Linder, Monika I.; Mizoguchi, Yoko; Hesse, Sebastian; Csaba, Gergely; Tatematsu, Megumi; Lyszkiewicz, Marcin; Zietara, Natalia; Jeske, Tim; Hastreiter, Maximilian; Rohlfs, Meino; Liu, Yanshan; Grabowski, Piotr; Ahomaa, Kaarin; Maier-Begandt, Daniela; Schwestka, Marko; Pazhakh, Vahid; Isiaku, Abdulsalam I.; Miranda, Brenda Briones; Blombery, Piers; Saito, Megumu K.; Rusha, Ejona; Alizadeh, Zahra; Pourpak, Zahra; Kobayashi, Masao; Rezaei, Nima; Unal, Ekrem; Hauck, Fabian; Drukker, Micha; Walzog, Barbara; Rappsilber, Juri; Zimmer, Ralf; Lieschke, Graham J.; Klein, Christoph

Journal: BLOOD. 2023; Vol. 141, Issue 6, pp. 645-658. DOI: 10.1182/blood.2022016783
3、C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse
Author: Yang, Li-Xue; Zhang, Cheng-Tao; Yang, Meng-Ying; Zhang, Xue-Hong; Liu, Hong-Chen; Luo, Chen -Hui; Jiang, Yue; Wang, Zhang-Man; Yang, Zhong-Yin; Shi, Zhao -Peng; Yang, Yi-Ci; Wei, Ruo-Qu; Zhou, Li; Mi, Jun; Zhou, Ai -Wu; Yao, Zhi-Rong; Xia, Li; Yan, Jin-Song; Lu, Ying

Journal: BLOOD. 2023; Vol. 141, Issue 7, pp. 766-786. DOI: 10.1182/blood.2022017046.
4、Cloned antibodies from patients with HIT provide new clues to HIT pathogenesis
Author: Zhu, Wen; Zheng, Yongwei; Yu, Mei; Wu, Yaling; Wei, Jianhui; Zhou, Lu; Fu, Guoping; Schneider, Nicholas; Jones, Curtis; Irani, Mehraboon; Padmanabhan, Anand; Aster, Richard; Wang, Demin; Wen, Renren

Journal: BLOOD. 2023; Vol. 141, Issue 9, pp. 1060-1069. DOI: 10.1182/blood.2022017612
5、A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
Author: Yu, Xiaoliang; Ma, Haikuo; Li, Bohan; Ji, Yuting; Du, Yayun; Liu, Siying; Li, Zhanhui; Hao, Yongjin; Tian, Sheng; Zhao, Cong; Du, Qian; Jin, Zhongqin; Zhu, Xueming; Tian, Yuanyuan; Chen, Xin; Sun, Xue; Yang, Chengkui; Zhu, Fang; Ju, Jie; Zheng, Yunjing; Zhang, Wei; Wang, Jingrui; Yang, Tao; Wang, Xinhui; Li, Jingjing; Xu, Xiangping; Du, Shujing; Lu, Haohao; Ma, Feng; Zhang, Haibing; Zhang, Yi; Zhang, Xiaohu; Hu, Shaoyan; He, Sudan

Journal: BLOOD. 2023; Vol. 141, Issue 9, pp. 1070-1086. DOI: 10.1182/blood.2022017262
6、Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation
Author: Zeng, Xiangjun; Li, Xiaoqing; Li, Xia; Wei, Cong; Shi, Ce; Hu, Kejia; Kong, Delin; Luo, Qian; Xu, Yulin; Shan, Wei; Zhang, Meng; Shi, Jimin; Feng, Jingjing; Han, Yingli; Huang, He; Qian, Pengxu

Journal: BLOOD. 2023; Vol. 141, Issue 14, pp. 1691-1707. DOI: 10.1182/blood.2022017514
7、Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Author: Kusumoto S¹, Arcaini L^2,³, Hong X⁴, Jin J⁵, Kim WS⁶, Kwong YL⁷, Peters MG⁸, Tanaka Y⁹, Zelenetz AD^10,¹¹, Kuriki H¹², Fingerle-Rowson G¹³, Nielsen T¹³, Ueda E¹², Piper-Lepoutre H¹³, Sellam G¹³, Tobinai K¹⁴.

Journal: Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.
8、The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses.
Author: Zhao Z¹, Wu Y^1,², Zhou J^1,², Chen F¹, Yang A¹, Essex DW².

Journal: Blood. 2019 Jan 17;133(3):246-251. doi: 10.1182/blood-2018-04-844480. Epub 2018 Nov 13.